Complementary and alternative medicine for respiratory tract infectious diseases: Prevention and treatments

Taixiang Wu
Sichuan University, txwutx@hotmail.com

Zhao-Xiang Bian
Hong Kong Baptist University, bzxiang@hkbu.edu.hk

Minawaer Abudu
Xinjiang University

Denise Adams
University of Alberta

Seong-Gyu Ko
Kyung Hee University

Follow this and additional works at: https://repository.hkbu.edu.hk/hkbu_staff_publication

Part of the Medicine and Health Sciences Commons

This document is the authors' final version of the published article.
Link to published article: http://dx.doi.org/10.1155/2014/913095

APA Citation
Wu, T., Bian, Z., Abudu, M., Adams, D., & Ko, S. (2014). Complementary and alternative medicine for respiratory tract infectious diseases: Prevention and treatments. Evidence-Based Complementary and Alternative Medicine, 2014, 913095. https://doi.org/10.1155/2014/913095

This Editorial is brought to you for free and open access by HKBU Institutional Repository. It has been accepted for inclusion in HKBU Staff Publication by an authorized administrator of HKBU Institutional Repository. For more information, please contact repository@hkbu.edu.hk.
Respiratory tract infectious diseases are a group of the most common, widespread diseases, from common cold and influenza to tuberculosis and pneumonia; some of them may cause serious and even life-threatening health problems. Most cases of upper respiratory tract infectious diseases include common cold and influenza, which are mainly caused by various virus infections, and tuberculosis, pneumonia, and other low respiratory tract infectious diseases caused by different bacterial infections.

Releasing the symptoms and preventing complicated bacterial infection are a rule of treating virus infected upper respiratory tract infectious diseases. Traditionally, herbal medicines are used to treat and prevent the respiratory tract infectious diseases such as common cold and influenza worldwide. For example, more than two hundred patent products of traditional Chinese medicines have been approved into market for treatment and prevention of the common cold as well as influenza. In the past decades, some herbal medicines are developed as injections for clinical use for treating respiratory tract infections, such as Caihu injection, Shuanghuanglian injection, Yuxincao injection, and Qinkailing injection. Some of these medicines are believed to effectively release the symptoms; some are believed to strengthen the immune function of patient and therefore result in the virus and bacteria being eliminated; some are believed to kill the microorganisms directly.

A fact is that although a lot of herbal medicines are widely used clinically, most evidence supporting their use came from poorly reported published clinical studies or studies with questionable methodology, as Drs. Q. Yang, H. Zhang, C. Zou, and L. Wu, concluded in their systematic reviews. Call for high quality evidence is a mission of this special issue.

Fortunately, Dr. J. Chang and her colleagues contributed high quality evidence about a patent Chinese medicine Shi-Cha capsule for common cold by a well-designed, well-conducted, and well-reported randomized controlled trial. In this multicenter study, they have done very well on the ethics issues including protocol approval by ethical committee, properly informed consent and registered their protocol in a public clinical trial registry—Chinese Clinical Trial Registry; and high quality methodological issues, including the randomization method and allocation procedure, the recruitment of patients, the data management, the analysis method of results, all of these were described in detail and very clearly according to CONSORT statement. This transparency makes readers confident to trust the result of the study and we believe such evidence should be graded as high quality. If the reporting refers to CONSORT for TCM to provide more information of the principle of using Shi-Cha capsule for with “wind-cold type common cold” will makes readers better understanding on the rational of this medicine. Another advantage of this trial is that placebo control was used for comparison with Shi-Cha capsule. Usually, use of a medicine in which “the effect is accepted by public recognition” as the control is one of rules of the new medicine development clinical trial in China. The shortcoming of this
rule is that it caused difficulty to assess the effects for a lot of
traditional Chinese medicines because of the lack of evidence
effect of the controls. For the self-limited disease, a placebo
control should be encouraged to be used in the treatment
study. We believe that this study and its report could be a good
example of high quality study and good reporting.

Another valuable thing we have seen is that Dr. C.
Zou and his colleagues, physicians of traditional Chinese
medicine, are using evidence-based medicine (EBM) method
to critically appraise the evidence and using the results to
guide their clinical practice successfully. This absolutely is
a revolutionary event in the field while most traditional
medical clinicians may not know EBM exactly. We hope more
and more clinicians in the field can use EBM method to guide
their practices and make the health care service better and
better.

Studies came from France, Japan, South Africa, and
Taiwan provide from in vitro and animal study suggesting
that some herbal medicines may have antimicrobial activity
or can strengthen the immune function. It is expected that
these lines of evidence will result in more confidence to
support the clinical use of complementary and alternative
medicines.

Taixiang Wu
Zhao-Xiang Bian
Minawaer Abudu
Denise Adams
Seong-Gyu Ko